Koyfin Home > Directory > Health Care > Adamas Pharma > EBITDA / Interest Expenses

Adamas Pharma EBITDA / Interest Expenses Chart (ADMS)

Adamas Pharma annual/quarterly EBITDA / Interest Expenses from 2012 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Adamas Pharma EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-2m a -168.29% increase of 3m year over year
  • Adamas Pharma EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-4m a -48.53% increase of 2m year over year
  • Adamas Pharma Annual EBITDA / Interest Expenses for 2019 was $-6m a -3.14% increase of 0m from 2018
  • Adamas Pharma Annual EBITDA / Interest Expenses for 2018 was $-6m a -214.03% increase of 13m from 2017
  • Adamas Pharma Annual EBITDA / Interest Expenses for 2017 was $-19m a 162.29% decrease of -30m from 2016
Other Ratios Metrics:
  • Adamas Pharma Total Debt / Capital for the quarter ending September 09, 2018 was $50m a -21.13% decrease of -11m year over year
  • Adamas Pharma Other Liabilities for the quarter ending December 12, 2018 was $3m a 76.22% increase of 2m year over year
  • Adamas Pharma Total Debt / Equity for the quarter ending September 09, 2018 was $101m a -53.94% decrease of -54m year over year
View Chart On Koyfin

Quarterly ADMS EBITDA / Interest Expenses Data

06/2020$-2m
03/2020$-3m
12/2019$-6m
09/2019$-5m
06/2019$-6m
03/2019$-7m
12/2018$-7m
09/2018$-5m
06/2018$-6m
03/2018$-6m

Annual ADMS EBITDA / Interest Expenses Data

2019$-6m
2018$-6m
2017$-19m
2013$12m
2012$10m
2011$-275m